Paper Details

  1. Home
  2. Paper Details

Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies.

Author: BeitingDaniel P, ChoChristina, DeRitaRachel M, DiehlJ Alan, FuchsSerge Y, KoumenisConstantinos, KrespanElise, KubanoffRyan, LuZhen, OrtizAngelica, PeckAmy R, RadaelliEnrico, RuiHallgeir, RyeomSandra W, SunYunguang, VerginadisIoannis I, YaspanAndrew T, YuPengfei, ZahediFarima, ZhangHongru

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study found that cholesterol 25-hydroxylase (CH25H) plays a critical role in suppressing intercellular biomolecule transfer (ICBT) between malignant and endothelial cells, which can lead to tumor growth and metastasis. Inhibition of ICBT with reserpine was effective in reducing angiogenesis and tumor growth, suggesting a potential novel treatment strategy for cancer.
Paper Details　
Original Abstract of the Article :
Intercellular biomolecule transfer (ICBT) between malignant and benign cells is a major driver of tumor growth, resistance to anticancer therapies, and therapy-triggered metastatic disease. Here we characterized cholesterol 25-hydroxylase (CH25H) as a key genetic suppressor of ICBT between malignant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121529/

データ提供：米国国立医学図書館（NLM）

Intercellular Biomolecule Transfer: A Hidden Player in Tumor Growth and Treatment Resistance

The fight against cancer is an ongoing battle, and this research delves into a previously underappreciated aspect of tumor growth: intercellular biomolecule transfer (ICBT). It's like discovering a hidden oasis in the vast desert of cancer research, revealing a new pathway that fuels tumor growth and contributes to treatment resistance. The authors identify cholesterol 25-hydroxylase (CH25H) as a key regulator of ICBT, playing a critical role in angiogenesis, tumor growth, and response to therapies. The study demonstrates that inhibiting ICBT can significantly enhance the efficacy of anticancer therapies. This groundbreaking research opens up new avenues for developing more effective treatments for cancer. The most notable finding is the identification of CH25H as a key regulator of ICBT and the potential for ICBT inhibition to improve the effectiveness of anticancer therapies.

Unlocking New Pathways for Cancer Treatment

This research is a significant breakthrough in the field of cancer research, unlocking new pathways for developing more effective treatments. It highlights the importance of understanding the intricate interactions between cells within the tumor microenvironment. The study's findings are a beacon of hope for patients with cancer, offering promising new approaches to combatting this devastating disease.

The Future of Cancer Treatment

This research is a testament to the ongoing quest for better cancer treatments. It opens up new avenues for developing more effective therapies, targeting the complex interactions between cells within the tumor microenvironment. The study's findings provide a roadmap for future research, leading to new breakthroughs in the fight against cancer.

Dr.Camel's Conclusion

This research is like uncovering a hidden oasis in the vast desert of cancer research, revealing the crucial role of intercellular biomolecule transfer in tumor growth and treatment resistance. The identification of CH25H as a key regulator of ICBT and the potential for ICBT inhibition to enhance therapy efficacy are significant breakthroughs. This research is a beacon of hope, paving the way for more effective treatments and improved outcomes in the fight against cancer.

Date :
  1. Date Completed 2021-10-05
  2. Date Revised 2021-10-05
Further Info :

Pubmed ID

33998600

DOI: Digital Object Identifier

PMC8121529

Related Literature

Article Analysis
・Side Effects of reserpine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.